|Endo International plc -- USA Stock|| |
USD 6.71 0.30 4.28%
Special Advisor to the CEO
Mr. Donald W. Degolyer is a Chief Operating Officer Pharmaceuticals.
353 1 268 2000 http://www.endo.com
Donald DeGolyer Latest Insider Activity
The company has return on total asset (ROA)
of 3.04 %
which means that it generated profit of $3.04 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of (77.37) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.31 B in liabilities. Endo International plc has Current Ratio of 1.0 suggesting that it is not liquid enough and may have problems to pay out its financial obligations when they are due.
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Endo International operates under Drug Manufacturers - Other classification in USA and traded on NASDAQ exchange. It employs 30 people.Endo International plc (ENDP) is traded on NASDAQ in USA. It is located in IRELAND and employs 3,039 people. Endo International is listed under Pharmaceutical Products category by Fama And French industry classification.